

China-Biotics Provides Updates on Qingpu New Facility and Chinese Probiotics Market

- Increased to 31 customers for Bulk Probiotics Products -
- Ministry of Health Announced Expanded List of Probiotics -

SHANGHAI, May 19, 2010 - **China-Biotics, Inc. ("China-Biotics", the "Company") (Nasdaq: CHBT)**, the leading developer, manufacturer and distributor of probiotics products in China, today announced that a number of its probiotics strains appear on the expanded probiotics list for food industry recently approved by the Ministry of Health in China.

China-Biotics currently carries all of the 21 probiotics strains in the list approved by the Ministry of Health. These probiotics strains are widely used in the Company's bulk additive products.

Mr. Jinan Song, Chairman and Chief Executive Officer of China-Biotics, commented, "We applaud the Chinese government's decision and support of wider uses of probiotics products. The number of probiotics strains on the list has doubled, which also demonstrates the rapidly expanding probiotics market in China. Changes in the Chinese people's dietary structure and greater concern over health issues due to the overuse of antibiotics in our food chain are calling for higher demands for probiotics products."

"Bulk production at our new production facility in Qingpu Industrial Park is ramping up as our products continue to gain traction among new and existing customers. We have increased both bulk additive probiotics customer numbers and expanded our geographic presence within China. Currently we have secured 31 bulk additive probiotics customers nationwide in tier-one urban areas such as Beijing and Shanghai as well as inland provinces such as Qinghai and Inner Mongolia," Mr. Song concluded.

About China-Biotics

China-Biotics, Inc. ("China-Biotics," "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements in China. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company develops and produces its proprietary product portfolio including live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang province. In February 2010, China-Biotics began its commercial production in China's largest probiotics production facility to meet growing demand in China. For more information, please visit <http://www.chn-biotics.com>.

Safe Harbor Statement

The information in this release contains forward-looking statements which involve risks and uncertainties, including statements regarding the Company's capital needs,

business strategy and expectations. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, which may be identified by terminology such as "may," "should," "will," "expect," "plan," "intend," "anticipate," "believe," "estimate," "predict," "potential," "forecast," "project," or "continue," the negative of such terms or other comparable terminology. Readers should not rely on forward-looking statements as predictions of future events or results. Any or all of the Company's forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions, risks and uncertainties and other factors which could cause actual events or results to be materially different from those expressed or implied in the forward-looking statements. In evaluating these statements, readers should consider various factors, including the risks described in "Item 1A. Risk Factors" beginning on page 15 and elsewhere in the Company's 2009 Annual Report on Form 10-K. These factors may cause the Company's actual results to differ materially from any forward-looking statement. In addition, new factors emerge from time to time and it is not possible for the Company to predict all factors that may cause actual results to differ materially from those contained in any forward- looking statements. The Company disclaims any obligation to publicly update any forward-looking statements to reflect events or circumstances after the date of this document, except as required by applicable law.

Contact:

Travis Cai
Chief Financial Officer
China-Biotics, Inc.
Email: traviscai@chn-biotics.com

Kevin Theiss
Grayling
Phone: +1-646-284-9409
Email: kevin.theiss@grayling.com